COMMUNIQUÉS West-GlobeNewswire

Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission
18/03/2026
Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE [...]
Equillium to Participate in the 38th Annual Roth Conference
18/03/2026
LA JOLLA, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that [...]
Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
18/03/2026
Company to host conference call to discuss financial results and provide a corporate update on March 25, 2026 at 4:30 p.m. ET SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey [...]
Engineered Silkworms Spin Spider Silk as Biotech Firm Targets Commercial Scale
18/03/2026
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- www.247marketnews.com -- A biotechnology company developing genetically engineered silkworms says it’s moving toward commercial production of spider silk, a material long [...]
Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results
18/03/2026
Advancing t ransformation into a d iversified b iomedical i nnovation c ompany with a c lear p ath to c ash f low p ositiv e Oramed s trategic t ransaction r eceives s hareholder a pproval ; Lifeward g ain s n ew o ral [...]
WallabyPhenox Restructures Debt and Accelerates Global Growth
18/03/2026
IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- WallabyPhenox, a global neurovascular medical technology company, today announced the successful completion of a significant financing round aimed at strengthening its [...]
Celcuity Schedules Release of Fourth Quarter and Full Year 2025 Financial Results and Webcast/Conference Call
18/03/2026
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its [...]
CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth
18/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) today announced that all proposals put forth at the Special Meeting of Stockholders [...]
JenaValve Announces FDA Approval of the Trilogy™ Transcatheter Heart Valve System — the First and Only Transcatheter Device Approved for Symptomatic, Severe Aortic Regurgitation (ssAR) in the United States
18/03/2026
Approval marks a historic milestone for Americans living with ssAR who are at high risk for surgery and previously had no dedicated transcatheter treatment option IRVINE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- [...]
VIVUS Confirms QSIVA® Price Reduction Is Now Effective Across Nordics and Poland
18/03/2026
— The lowered pricing structure is now available for 963,88 SEK per bottle at pharmacies throughout Sweden AMSTERDAM, March 18, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical company [...]
SS Innovations’ SSi Mantra Surgical Robotic System Approved for Telesurgeries in Indonesia and the Philippines
18/03/2026
Company surpasses milestone of 150 cumulative telesurgeries successfully performed with the SSi Mantra FORT LAUDERDALE, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS [...]
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting
18/03/2026
WESTLAKE VILLAGE, Calif., and DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno- [...]
Prenetics to Participate in the 38th Annual ROTH Conference
18/03/2026
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (PRE) (“Prenetics” or the “Company”), a leading consumer health sciences company and parent of the IM8 premium health and longevity brand, today [...]
60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract
18/03/2026
FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option agreement with [...]
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
18/03/2026
• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics toolkit • NIH-funded project leverages collaborators’ expertise [...]
Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe
18/03/2026
First Commercial Order by Large Lab Chain: Biomerica has received its first commercial order for Hp Detect™, from one of the largest clinical laboratory chains operating across Europe. Strategic Account: This new lab’s [...]
Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit
18/03/2026
NORWOOD, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused promising new therapies in oncology and obesity, today announced that Yuval Cohen [...]
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study
18/03/2026
Investigator-sponsored trial backed by Glaucoma UK and HSC R&D Division targets rapidly growing patient population; first enrollment expected Q2 2026 BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo [...]
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
18/03/2026
Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals with high baseline CSF [...]

Pages